Fiscal year ending 2024. Filed on October 23, 2025.
830 Glenwood Ave SE 510-323
Atlanta, Georgia 30316
Odylia Therapeutics Inc. (EIN: 82-2120760) has filed an IRS Form 990 since fiscal year 2018. In its fiscal year 2024 IRS Form 990 filing, Odylia Therapeutics Inc., a 501(c)(3) charitable organization, reported compensation for 2 out of 4 total employees. Among the employees shown here, the average compensation is $170,741. The highest compensated employee at Odylia Therapeutics Inc. is Ashley Winslow with fiscal year 2024 compensation of $225,220.
Revenue
Expenses
Employee compensation
ODLYIA'S MISSION IS TO FACILITATE THE RESEARCH OF GENETICS, GENETIC THERAPIES AND SAFE AND EFFECTIVE TREATMENTS THAT ADDRESS RARE AND ULTRA-ARE DISEASES, INCLUDING TO (I) RESEARCH AND DEVELOP METHODOLOGIES FOR MORE EFFECTIVE AND EFFICIENT DEVELOPMENT OF THERAPIES AND TREATMENTS OF RARE AND ULTRA-RARE DISEASES INCLUDING, BUT NOT LIMITED TO, THE CONDUCT AND OVERSIGHT OF CLINICAL TRIALS, (II) COMPILE AND DISSEMINATE SCIENTIFIC LITERATURE THAT PROMOTES AND ATTRACTS RESOURCES FOR RESEARCH AND THE DEVELOPMENT OF THERAPIES AND TREATMENTS THAT ADDRESS RARE AND ULTRA-RARE DISEASES, (III) DEVELOP BEST PRACTICES IN THE FIELD OF RESEARCH AND THE DEVELOPMENT OF TREATMENTS OF RARE AND ULTRA-RARE DISEASES AND (IV) ENGAGE IN AND CARRY ON ANY SUCH OTHER ACTIVITIES IN FURTHERANCE OF SUCH PURPOSES AS NONPROFIT CORPORATIONS ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW MAY CONDUCT, BUT ONLY TO THE EXTENT THAT SUCH ACTIVITIES SHALL BE PERMITTED UNDER SECTION 50L(C)(3) OF THE CODE.
Be the first to know when new IRS Form 990 data is published for this organization.